#154 - EXTERNAL VALIDATION OF A NEW TELEMEDICINE MOBILE APPLICATION ADDRESSED TO SPANISH-SPEAKING PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DAMASCO AND DAMASCO-DOCTOR

Puga M[1], Sanchez M[2], Chilan A[2], Conlon C[3], Spiazzi R[3], Cerezo J[3], Omonte A[3], Milano C[3], Oleas R[4], Arevalo M[1], Baquerizo J[1], Egas M[1], Cunto D[1], Robles C[1], Pitanga H[1], Iade B[5], Arriola M[5], Rainero G[6], Meligrana N[6], Valero M[7], Koll L[7], Martinez M[7], Simian D[8], Maulen C[8], Estay C[8], García C[9], Bellido A[10], Ojeda M[10], Azañedo C[11], Marriott E[12], Marriott D[12], Andrade D[13], Espinoza J[13], Vlcek K[14], Garcete J[14], Martin J[15], Faia Y[16]

[1]Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador [2]mdconsgroup, Guayaquil, Ecuador [3]Hospital Nacional Profesor Alejandro Posadas (HNPAP), El Palomar, Argentina [4]John H. Stroger, Jr. Hospital of Cook County, Chicago, Estados Unidos (EEUU) [5]Centro de Asistencia del Sindicato Médico del Uruguay (CASMU), Montevideo, Uruguay [6]Hospital Universitario Austral (HUA), Pilar, Argentina [7]Instituto de Gastroenterología y Endoscopía de Avanzada (IGEA), Bahía Blanca, Argentina [8]Hospital Clínico Universidad de Chile (HCUCH), Santiago, Chile [9], Lima, Perú [10]Hospital Cayetano Heredia (HCH), Lima, Perú [11]Clinica Internacional, Lima, Perú [12]Hospital de Especialidades Teodoro Maldonado Carbo (HTMC),, Guayaquil, Ecuador [13]Hospital de Especialidades José Carrasco Arteaga (HJCA), Cuenca, Ecuador [14]Hospital Central del Instituto de Previsión Social (HC-IPS), Asunción, Paraguay [15]Universidad Católica de Santiago de Guayaquil (UCSG), Guayaquil, Ecuador [16]Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brasil

BACKGROUND: Damasco is a telemedicine mobile app for Spanish-speaking's with inflammatory bowel disease (IBD). Its prototype, previously evaluated in a single-centre study, proved to be intuitive and IBD-specific. Some user-patients suggested the participation of healthcare professionals. Damasco is not linked to any hospital. It is free to access. Since June/2023, both Damasco and Damasco-Doctor have been available on iOS and Google Play. Damasco-Doctor is a read-only user for healthcare professionals, to track data from whom follow them.

AIM: To externally validate Damasco through a user-patient acceptance test (UPAT).

METHODS: We contacted IBD users-patients through social media (Facebook/WhatsApp), to assess Damasco and its interaction with Damasco-Doctor. Damasco has been developed in JavaScript, with the following functions: medication reminder, stool characteristics, meals photo-documentation, GPS bathroom finder and e-Learning module. Through a link, the user-patients authorize a Damasco-doctor user to track information. The UPAT was performed using the Mobile Application Rating Score (MARS). A Likert (L) 4-5 (very good-excellent) >80% was the reference.

RESULTS: 53 surveys were retrieved, 40/53 answered ≥70% MARS: median age 34.5 (32-49), 33/40 women; 11/40 foreign surveyed (27.5%); 23/40 public hospitals (57.5%); 22/40 ulcerative colitis (55%), 17/40 Crohn's disease, 1/40 unclassifiable colitis. There was a higher scoring regarding functionality (L4-5 92.5%), content (89.2%), design (84.2%) and app adherence (66.5%) (**Figure 1**). Compared to the prototype, there was a significant improvement in the content (76.5%; p<.05) and design (68.7%; p<.05).Damasco was scored with four to five stars by 31/40 (77.5%) and 9/40 (22.5%), respectively. Damasco is a specific IBD app according to 94% of surveyed.

CONCLUSION: Damasco and Damasco-Doctor are high-acceptance tools among IBD Spanish-speaking users-patients. Joint symptoms and a test reminder (colonoscopy, calprotectin) are pending functions. An update must also improve app adherence. This external validation must be completed on a worldwide scale.

Figure 1. A 5-item Likert scala (L)-based Mobile Application Rating Score (MARS). A higher scoring is related to a higher Damasco app acceptance.